RE:RE:RE:Pfizer pivots to 'externalization" of rare disease programs westcoast - In August ONCY reported that : "Clinical biomarker data show pelareorep remodeling tumor microenvironments to improve prognosis and decrease the risk of recurrence in HR+/HER2- breast cancer patients"
With ONCY reporting that pelareorep clinical data was demonstrating pelareorep's ability to remodel the TME and also knowing NOW that both the TME and an activated IFN gamma pathway are key to stimulating the innate and adaptive immune system along with the prevention T-cell exhaustion, any co-development partner like Pfizer or MerckKGaA involved in a minority represented breast cancer trial, and who has also seen the recent achievement of pelareorep + atezolizumab in pancreatic cancer, would be delinquent to its shareholders if those partners do not engage in partnership or acquisition talks with ONCY. The same applies to Roche and other Big Pharma companies, even though these others are not priviledged to the Bracelet-1 clinical trial data the same way that Pfizer and MerckKGaA have been and will be next approximate 30 - 35 days,